Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.
I’m a snowflake… Because every person, empirically, is unique.” — Faith Salie, American journalist Hello Downriver, I got more than a few emails about last week’s column, and ...